Health Catalyst (NASDAQ:HCAT) Price Target Raised to $9.00 at Stephens

Health Catalyst (NASDAQ:HCAT) had its target price increased by Stephens from $7.00 to $9.00 in a report issued on Thursday,Benzinga reports. Stephens currently has an equal weight rating on the stock.

Several other equities research analysts have also weighed in on the company. Evercore ISI raised their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. JPMorgan Chase & Co. raised their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Royal Bank of Canada raised their price objective on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Piper Sandler reduced their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.71.

Health Catalyst Stock Performance

Shares of NASDAQ HCAT opened at $7.65 on Thursday. The firm has a market cap of $465.50 million, a P/E ratio of -5.67 and a beta of 1.32. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. The stock has a fifty day moving average price of $8.16 and a two-hundred day moving average price of $7.23. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $11.41.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). The company had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.22) earnings per share. Research analysts forecast that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares in the company, valued at approximately $1,847,460.82. This trade represents a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total value of $40,005.12. Following the sale, the chief operating officer now owns 134,899 shares of the company’s stock, valued at approximately $1,036,024.32. This represents a 3.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,068 shares of company stock worth $257,555. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors have recently bought and sold shares of the stock. Principal Financial Group Inc. raised its holdings in Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after buying an additional 1,907 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in Health Catalyst by 21.3% during the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after buying an additional 2,064 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Health Catalyst by 10.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after buying an additional 2,164 shares in the last quarter. Creative Planning raised its holdings in Health Catalyst by 13.2% during the third quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after buying an additional 2,486 shares in the last quarter. Finally, Quarry LP raised its holdings in Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after buying an additional 2,610 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.